← Back to Search

P2Y12 Inhibitor

Cangrelor for Acute Coronary Syndrome (SWAP-6 Trial)

Phase 4
Waitlist Available
Led By Francesco Franchi, MD
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 hours
Awards & highlights

SWAP-6 Trial Summary

This trial is investigating whether there is a drug interaction when cangrelor and prasugrel are given together to patients undergoing coronary stenting.

Eligible Conditions
  • Acute Coronary Syndrome
  • Coronary Artery Disease

SWAP-6 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Platelet Reactivity Measured by VerifyNow

Side effects data

From 2018 Phase 4 trial • 50 Patients • NCT03247738
12%
minor bleeding
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cangrelor
Placebo

SWAP-6 Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Prasugrel + CangrelorExperimental Treatment2 Interventions
Cangrelor plus prasugrel concomitantly administered at the start of PCI
Group II: PrasugrelActive Control1 Intervention
Prasugrel only administered at the start of PCI
Group III: Cangrelor followed by PrasugrelActive Control2 Interventions
Cangrelor administered at the start of PCI plus prasugrel administered at the end of the cangrelor infusion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Prasugrel
2013
Completed Phase 4
~24920
Cangrelor
2013
Completed Phase 4
~710

Find a Location

Who is running the clinical trial?

Scott R. MacKenzie FoundationOTHER
4 Previous Clinical Trials
147 Total Patients Enrolled
University of FloridaLead Sponsor
1,338 Previous Clinical Trials
714,994 Total Patients Enrolled
3 Trials studying Acute Coronary Syndrome
1,694 Patients Enrolled for Acute Coronary Syndrome
Francesco Franchi, MDPrincipal InvestigatorUniversity of Florida
5 Previous Clinical Trials
669 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who is qualified to be enrolled in this medical research?

"This clinical trial seeks out 90 individuals between 18 and 75 years old who have been diagnosed with coronary artery disease. To meet the eligibility criteria, they must be suffering from NSTE-ACS (UA or NSTEMI) following PCI; an electrocardiogram displaying cardiac ischemic symptoms can confirm this diagnosis, though a normal reading may also suffice if the attending clinician believes it to demonstrate ACS presentation."

Answered by AI

Can you provide any other examples of research on Cangrelor?

"At present, 16 studies are underway to study Cangrelor. Of these clinical trials, 3 have moved into Stage 3 of testing. Many tests for this treatment are located in Kansas City, Kansas with a total of 515 sites across the US running related research."

Answered by AI

Is this research experiment currently recruiting participants?

"As evidenced by the clinicaltrials.gov page, this research study is actively enrolling participants. This experiment was first announced on February 9th 2021 and underwent an update as recent as October 18th 2022."

Answered by AI

What ailment is Cangrelor commonly administered to alleviate?

"Cangrelor is typically used to address cardiovascular events, although it also shows efficacy in prophylaxis of stent thrombosis, percutaneous coronary intervention and coronary revascularization."

Answered by AI

How risk-free is the use of Cangrelor for individuals?

"Given the late-stage nature of this clinical trial, Cangrelor has been assigned a safety score of 3. This rating reflects approval by regulatory authorities and extensive prior data collection."

Answered by AI

How many participants are currently participating in this experiment?

"Affirmative. Clinicaltrials.gov displays that this study is actively looking for patients to participate and was initially posted on February 9th 2021 with the last update occurring on October 18th 2022. This trial requires 90 people from a single medical centre."

Answered by AI

Can those aged 18 or older take part in this medical experiment?

"This clinical trial has set the age criteria from 18 to 75 years old. For younger demographics, there are 394 trials available and for senior citizens 1560 studies have been listed."

Answered by AI
~88 spots leftby Apr 2025